retatrutide phase 2 study results Effects of on body composition in people with type diabetes: a substudy of a 2, double-blind, parallel-group, placebo-controlled, randomised trial Phase 2 trial results demonstrate

Clinical trial data from the SURMOUNT-1 study showed that up to 29% of participants on tirzepatide for weight loss experienced nausea, primarily during dose escalation phases

Smaller portions, higher protein, and functional ingredients are quickly becoming baseline expectations across the food industry

No studies have evaluated this practice, so I cannot speak to its effects in a controlled setting

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

Injection of unverified, unsterile compounds carries infection and inflammatory risks that are independent of any effects the peptide itself might or might not have